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ABSTRACT
Background and Objectives: The extent of coronary artery calcification (CAC) is closely related to total atherosclerotic 
plaque burden. However, the pathogenesis of CAC is still unclear. Conditions such as diabetes mellitus, renal failure, smoking, 
and chronic inflammation have been suggested to link vascular calcification and bone loss. In the present study, we hypothe-
sized that bone loss can contribute to the pathogenesis of CAC in patients with the chronic inflammatory condition that ac-
companies metabolic syndrome (MetS). The objective of this study was to investigate the relationship between CAC and bone 
mineral density (BMD) in patients with MetS and in patients without MetS, by using coronary multidetector-row computed 
tomography (MDCT). Subjects and Methods: Data from 395 consecutive patients was analyzed retrospectively. From the 
MDCT database, only those patients who underwent both coronary MDCT and dual-energy X-ray absorptiometry within an 
interval of one month, were selected. The presence of MetS was determined by the updated criteria as defined by the Third 
Adult Treatment Panel Report of the National Cholesterol Education Program. Results: In patients with MetS, a significant 
correlation was found between CAC and age {odds ratio (OR)=1.139, 95% confidence interval (CI) 1.080 to 1.201, p<0.001}, 
CAC and male sex (OR=3.762, 95% CI 1.339 to 10.569, p=0.012), and CAC and T-score of L-spine (OR=0.740, 95% CI 0.550 
to 0.996, p=0.047) using a forward multiple logistic regression analysis model including clinical variables of gender, age, lipid 
profile, body mass index, diabetes mellitus, hypertension, smoking, and BMD. But in patients without MetS, BMD by itself was 
not found to contribute to CAC. Conclusion: BMD was inversely correlated with CAC only in patients with MetS. This find-
ing suggests that low BMD accompanied by MetS, may have significant clinical implications. (Korean Circ J 2011;41:76-82)
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Introduction
Coronary artery calcification (CAC) has been shown to play 
an important role of a risk marker in the development of ath-
erosclerosis.
1) CAC is closely related to total atherosclerotic 
plaque burden.
1) However, the pathogenesis of CAC is still un-
clear. Some studies have suggested that the degree of CAC cor-
relates with local vascular inflammation.
2)3)
Metabolic syndrome (MetS) is associated with low-grade 
systemic inflammation.
4) MetS is characterized by clustering 
of cardiovascular risk factors including central adiposity, in-
sulin resistance, hypertension, dyslipidemia, and a proinflam-
matory state.
5) Some studies have shown that both insulin re-
sistance and atherosclerosis share a common inflammatory 
process.
6) 
Controversially, some studies have reported the association 
between low bone mineral density (BMD) and coronary ar-
tery disease.
7)8) Several mechanisms have been suggested to 
link vascular calicification and bone loss, including ageing, di-Hyung Tak Lee, et al.   77
abetes mellitus, renal failure, smoking, chronic inflammation, 
and oxidative stress.
9) In the present study, we hypothesized 
that bone loss can contribute to the pathogenesis of CAC in pa-
tients with the chronic inflammatory condition that accom-
panies MetS. Hence in this study, we aimed to investigate the 
relationship between CAC and BMD in patients with MetS 
and in patients without MetS, by using coronary multidetec-
tor-row computed tomography (MDCT).
Subjects and Methods
Study population
The dataset was acquired from the MDCT database at the 
Hanyang University Hospital, Seoul, Korea, from March 29th 
2007 to June 25th 2009. From this database 3,521 patients who 
underwent both coronary MDCT and dual-energy X-ray ab-
sorptiometry (DEXA) within an interval of one month were en-
rolled. Finally, data from 395 consecutive patients was analyz-
ed retrospectively. 
All of these patients had undergone physical examination 
at the health promotion center. A fasting lipid profile {total cho-
lesterol, high density lipoprotein-cholesterol  (HDL-C), low 
density lipoprotein-C (LDL-C), and triglycerides} plus blood 
glucose tests were performed on each of the study participant. 
Blood pressure (BP) was measured by a mercury sphygmoma-
nometer by the physician and the average of at least two mea-
surements taken five minutes apart, were recorded. Weight and 
height of each study participant, for calculation of the body 
mass index (BMI) (kg/m
2) were also recorded at the same vis-
it. Clinical information was collected by reviewing each pa-
tient’s medical records. 
Prevalent diabetes was defined as a self-report of a history of 
being told by a physician that he/she had diabetes or was hav-
ing a fasting blood glucose level of greater than or equal to 126 
mg/dL. Hypertension was defined as average BP of at least 
140/90 mmHg on two consecutive measurements taken five 
minutes apart or undergoing antihypertensive drug treat-
ment due to a history of hypertension. The presence of MetS 
was determined by the updated criteria as defined by the Th-
ird Adult Treatment Panel (ATP III) Report of the National 
Cholesterol Education Program.
10) We modified the criteria 
and we used BMI ≥25 kg/m
2 instead of waist circumference 
cutpoints.
11) Subjects with three or more of the following cri-
teria: 1) BMI ≥25 kg/m
2; 2) Serum triglycerides levels of ≥150 
mg/dL or undergoing drug treatment for elevated serum tri-
glycerides levels ; 3) HDL-C levels of ≤40 mg/dL in men and 
≤50 mg/dL in women or undergoing drug treatment for low 
HDL-C; 4) fasting blood glucose level of ≥100 mg/dL or un-
dergoing drug treatment for elevated fasting blood glucose 
level ; or 5) BP of at least 130/85 mmHg or undergoing anti-
hypertensive drug treatment due to a history of hypertension.
The study protocol was approved by the Institutional Re-
view Board of the Hanyang University Hospital. 
 
Coronary calcification measurements
CT scans were performed on a 64-MDCT scanner (Bril-
liance 64, Philips Medical Systems, Best, The Netherlands). 
About sixty, 0.9-mm thick slices of the coronary arteries were 
obtained during a single breath-hold for the time period of 
15-20 seconds, using prospective electrocardiography-gated 
axial scanning. All the CT images were analyzed for the pres-
ence and the extent of CAC according to the Agatston method, 
by using the coronary calcium quantification software (Aqu-
arius workstation, TeraRecon, Inc., San Mateo, CA, USA).
12)
Bone mineral density measurements
BMD was measured at the lumbar spine (L-spine) and fe-
mur using DEXA (Discovery-W, Hologic Inc., Bedford, MA, 
USA). The results were interpreted in terms of BMD (g/cm
2) 
and the T-score. T-score was calculated by taking the difference 
between a patient’s measured BMD and the mean BMD of he-
althy young adults matched for gender and ethnicity, and di-
viding by the standard deviation (SD) of the young adult po-
pulation. 
Statistical analysis
All data are presented as the means and standard deviations, 
and statistical analysis was performed using Statistical Pack-
age for the Social Sciences (SPSS, version 13.0; SPSS Inc., Chi-
cago, IL, USA). A p<0.05 was considered statistically significant.
Student’s t-test was used for comparison of measured values 
between the two groups divided according to the presence 
of MetS. In order to compare the significance between the 
two groups, chi-square test was used. Univariate logistic re-
gression analyses were used to identify the relationship be-
tween CAC and clinical variables. In the univariate logistic re-
gression analysis; lipid profile, fasting blood glucose, age, BP, 
BMD, and BMI were analyzed as continuous variables.
In the total patients, three multiple logistic regression anal-
ysis models were used to estimate the independent correla-
tion between CAC and clinical variables. Gender, age, smok-
ing, BMD, LDL-C, MetS, and interaction of MetS with BMD 
were included as in all the models. Collinearity was present 
between MetS and hypertension, MetS and diabetes melli-
tus, MetS and BMI, MetS and triglycerides, and MetS and 
HDL-C. Hence these risk factors associated with MetS, were 
excluded from the models for the total patients. For the total 
patients, in the first model T-score of L-spine was included. In 
the second model, T-score of femur was included. In the third 
model, T-scores of both L-spine and femur were included. 
In patients with MetS and in patients without MetS, three 
multiple logistic regression analysis models were also used to 
estimate the independent correlation between CAC and cli-
nical variables. Due to the exclusion of MetS from the analy-78   CAC and BMD According to Patient’s MetS Status
sis models, gender, age, lipid profile, BMI, diabetes mellitus, 
hypertension, smoking, and BMD were included in all the 
models. Collinearity was seen between LDL-C level and st-
atin medication. Collinearity was also seen between hyper-
tension status and antihypertensive medication. Hence,  we 
excluded medication status from all the multiple logistic re-
gression models. The inclusion criterion for the forward mul-
tiple logistic regression analysis was p<0.05 while the exclu-
sion criterion was p>0.10. In all the multiple logistic regress-
ion analysis, lipid profile, age, BMD, and BMI were analyzed 
as continuous variables. Odd ratio (OR) is presented with 95% 
confidence interval (CI) in parenthesis.
Results
General characteristics of the subjects
The clinical characteristics of the study population are dis-
played in Table 1. The mean (±SD) age of the subjects was 51± 
10 years and the proportion of males was 55.9%. Proportion 
of diabetes was 11.6%, proportion of hypertension was 32.7%, 
and proportion of MetS was 33.2%. 
In the two groups divided by the presence of MetS, there 
were 264 subjects without MetS and there were 131 subjects 
with MetS. The significant differences between the group wi-
thout MetS versus the group with MetS respectively were as 
follows: proportion of males: 50.3% vs. 67.1%, p=0.002, BMI: 
23.66±3.26 vs. 26.68±3.00 kg/m
2, p<0.001, office systolic BP: 
118±15 vs. 129±15 mmHg, p<0.001, office diastolic BP: 72± 
10 vs. 79±10 mmHg, p<0.001, Fasting blood glucose: 89±20 
vs. 107±33 mg/dL, p<0.001, HDL-C: 50.3±11.9 vs. 38.9±7.8 
mg/dL, p<0.001, triglycerides: 115.0±74.6 vs. 189.4±96.8 mg/ 
dL, p<0.001, proportion of CCS >0: 20.4% vs. 43.5%, p<0.001, 
proportion of smokers: 40.5% vs. 50.4%, p=0.018, propor-
tion of diabetes mellitus: 4.5% vs. 25.9%, p<0.001, and pro-
portion of hypertension: 19.3% vs. 59.5%, p<0.001 (Table 2).
 
Crude relationship between coronary artery 
calcification and clinical variables
Univariate correlation between CAC and clinical variables 
are listed in Table 3. A significantly positive correlation was fo-
und between: CAC and age (OR=1.112, 95% CI 1.082 to 1.142, 
p<0.001), CAC and male sex (OR=3.338, 95% CI 2.041 to 
5.461, p<0.001), CAC and BMI (OR=1.066, 95% CI 1.002 to 
1.134, p=0.044), CAC and office systolic BP (OR=1.023, 95% 
CI 1.010 to 1.037, p=0.001), CAC and office diastolic BP 
(OR=1.032, 95% CI 1.011 to 1.053, p=0.002), CAC and fast-
ing blood glucose (OR=1.017, 95% CI 1.007 to 1.027, p<0.001), 
CAC and triglycerides (OR=1.003, 95% CI 1.001 to 1.005, 
p=0.016), CAC and diabetes mellitus (OR=4.483, 95% CI 
2.373 to 8.469, p<0.001), CAC and hypertension (OR=3.875, 
95% CI 2.440 to 6.155, p<0.001), CAC and MetS (OR=2.995, 
95% CI 1.897 to 4.730, p<0.001), and CAC and smoking (OR= 
1.596, 95% CI 1.027 to 2.481, p=0.038).
CAC was inversely correlated with T-score of femur (OR= 
0.774, 95% CI 0.628 to 0.955, p=0.017), with T-score of L-
spine (OR=0.826, 95% CI 0.699 to 0.976, p=0.025), and with 
HDL-C (OR=0.958, 95% CI 0.938 to 0.979, p<0.001).
 
Independent relationship between coronary artery 
calcification and clinical variables in the total patients
In the three multiple logistic regression analysis models, a 
significant correlation was found between: CAC and age (OR 
=1.148, 95% CI 1.111 to 1.187, p<0.001), CAC and male sex 
(OR=7.188, 95% CI 3.790 to 13.631, p<0.001), and CAC and 
MetS (OR=2.850, 95% CI 1.642 to 4.948, p<0.001) (Table 4). 
T-score of femur and/or L-spine was not an independent pre-
dictor of CAC. No significant correlation was found between 
CAC and the interaction between MetS and BMD.
Independent relationship between coronary artery 
calcification and clinical variables in patients without 
metabolic syndrome
In the three multiple logistic regression analysis models, a 
Table 1. Clinical characteristics of the patients
Age (year) 51±10
Male (%) 221/395 (55.9)
BMI (kg/m
2) 24.66±3.48
Office systolic BP (mmHg) 121±16
Office diastolic BP (mmHg) 074±11
T-score of femur -0.21±1.05
T-score of L-spine 2-4 -0.48±1.35
Fasting blood glucose (mg/dL) 095±27





CCS >0 (%) 111/395 (28.1)
Smoking (%) 177/395 (44.8)
Diabetes mellitus (%) 046/395 (11.6)
Hypertension (%) 129/395 (32.7)
Metabolic syndrome (%) 131/395 (33.2)
Medication (%)
    ACEi/ARB 28/395 (7.1)
    CCB 059/395 (14.9)
    β-blocker 11/395 (2.8)
    Statin 26/395 (6.6)
Data is reported as mean (±SD) or percentage. BMI: body mass in-
dex, BP: blood pressure, L-spine: lumbar spine, LDL-C: low density 
lipoprotein-cholesterol, HDL-C: high density lipoprotein-choles-
terol, CCS: coronary calcium score, ACEi: angiotensin converting en-
zyme inhibitor, ARB: angiotensin receptor blocker, CCB: calcium 
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significant correlation was found between: CAC and age (OR= 
1.141, 95% CI 1.089 to 1.195, p<0.001), CAC and male sex (OR 
=10.101, 95% CI 4.165 to 24.496, p<0.001), CAC and diabe-
tes mellitus (OR=7.822, 95% CI 1.451 to 42.174, p=0.017) and 
CAC and hypertension (OR=4.779, 95% CI 2.036 to 11.219, 
p<0.001) (Table 5). T-score of femur and/or L-spine was not 
an independent predictor of CAC.
Independent relationship between coronary artery 
calcification and clinical variables in patients with 
metabolic syndrome
In the multiple logistic regression analysis model including 
T-score of L-spine, a significant correlation was found between: 
CAC and age (OR=1.139, 95% CI 1.080 to 1.201, p<0.001), 
CAC and male sex (OR=3.762, 95% CI 1.339 to 10.569, p= 
0.012), and CAC and T-score of L-spine (OR=0.740, 95% CI 
0.550 to 0.996, p=0.047) (Table 6).
In the multiple logistic regression analysis model includ-
ing T-score of femur, a significant correlation was found be-
tween: CAC and age (OR=1.137, 95% CI 1.078 to 1.199, p< 
0.001), CAC and male sex (OR=3.800, 95% CI 1.354 to 
10.663, p=0.011), and CAC and T-score of femur (OR=0.670, 
Table 2. Comparison of the clinical characteristics between the two patient groups, divided by the presence of metabolic syndrome
Variable Without MetS (n=264) With MetS (n=131) p
Age (years) 51±9 052±11 0.223
Male (%) 133/264 (50.3) 88/131 (67.1) 0.002
BMI (kg/m
2) 23.66±3.26 26.68±3.00 <0.001
Office systolic BP (mmHg) 118±15 129±15 <0.001
Office diastolic BP (mmHg) 072±10 079±10 <0.001
T-score of femur -0.24±0.98 -0.16±1.19 0.443
T-score of L-spine 2-4 -0.53±1.24 -0.37±1.55 0.279
Fasting blood glucose (mg/dL) 089±20 107±33 <0.001
Total cholesterol (mg/dL) 205.1±38.0 201.8±38.4 0.411
LDL-C (mg/dL) 122.7±30.9 123.6±31.8 0.807
HDL-C (mg/dL) 050.3±11.9 38.9±7.8 <0.001
Triglycerides (mg/dL) 115.0±74.6 189.4±96.8 <0.001
Smoking (pys) 010.6±16.0 012.9±16.5 0.180
CCS > 0 (%) 054/264 (20.4) 57/131 (43.5) <0.001
Smoking (%) 107/264 (40.5) 70/131 (53.4) 0.018
Diabetes mellitus (%) 12/264 (4.5) 34/131 (25.9) <0.001
Hypertension (%) 051/264 (19.3) 78/131 (59.5) <0.001
Medication (%)
  ACEi/ARB 07/264 (2.6) 21/131 (16.0) <0.001
  CCB 23/264 (8.7) 36/131 (27.4) <0.001
  β-blocker 03/264 (1.1) 8/131 (6.1) 0.008
  Statin 09/264 (3.4) 17/131 (12.9) 0.001
Data is reported as mean (±SD) or percentage. MetS: metabolic syndrome, BMI: body mass index, BP: blood pressure, L-spine: lumbar spine, 
LDL-C: low density lipoprotein-cholesterol, HDL-C: high density lipoprotein-cholesterol, CCS: coronary calcium score, ACEi: angiotensin 
converting enzyme inhibitor, ARB: angiotensin receptor blocker, CCB: calcium channel blocker
Table 3. Univariate correlation between coronary artery calcifica-
tion and clinical variables using a univariate logistic regression 
analysis
OR 95% CI p
Age (year) 1.112 1.082 to 1.142 <0.001
Male 3.338 2.041 to 5.461 <0.001
BMI (kg/m
2) 1.066 1.002 to 1.134 0.044
Office systolic BP (mmHg) 1.023 1.010 to 1.037 0.001
Office diastolic BP (mmHg) 1.032 1.011 to 1.053 0.002
T-score of femur 0.774 0.628 to 0.955 0.017
T-score of L-spine 2-4 0.826 0.699 to 0.976 0.025
Fasting blood glucose (mg/dL) 1.017 1.007 to 1.027 <0.001
LDL-C (mg/dL) 1.001 0.994 to 1.008 0.746
HDL-C (mg/dL) 0.958 0.938 to 0.979 <0.001
Triglycerides (mg/dL) 1.003 1.001 to 1.005 0.016
Diabetes mellitus 4.483 2.373 to 8.469 <0.001
Hypertension  3.875 2.440 to 6.155 <0.001
Metabolic syndrome 2.995 1.897 to 4.730 <0.001
Smoking 1.596 1.027 to 2.481 0.038
OR: odds ratio, CI: confidence interval, BMI: body mass index, BP: 
blood pressure, L-spine: lumbar spine, LDL-C: low density lipopro-
tein-cholesterol, HDL-C: high density lipoprotein-cholesterol80   CAC and BMD According to Patient’s MetS Status
95% CI 0.453 to 0.992, p=0.045) (Table 6).
In the multiple logistic regression analysis model includ-
ing T-scores of both femur and L-spine, a significant correla-
tion was found between: CAC and age (OR=1.139, 95% CI 
1.080 to 1.201, p<0.001), CAC and male sex (OR=3.762, 95% 
CI 1.339 to 10.569, p=0.012), and CAC and T-score of L-spine 
(OR=0.740, 95% CI 0.550 to 0.996, p=0.047) (Table 6).
Discussion
The main finding of this study is that BMD is an indepen-
dent determinant of CAC, only in patients with MetS. BMD 
is not an independent predictor of CAC in total patients nor 
in patients without MetS. Based on this finding, we could 
speculate that low BMD may contribute to the pathogenesis 
of CAC only in those patients with the low-grade chronic in-
flammatory condition that accompanies MetS. 
A few studies have documented the increased risk of cor-
onary atherosclerosis associated with CAC, in the subjects 
with low BMD.
7)8)13) However, it is still unclear whether low 
BMD can be an independent predictor of CAC, even after a 
careful adjustment of the other risk factors for coronary ar-
tery disease. In the present study, no statistically significant 
correlation was found between CAC and BMD in the total 
patients, nor in the patients without MetS. These findings are 
partially consistent with some studies which suggest that bone 
loss and CAC are two independent processes.
14)15) From a cli-
nical viewpoint, the results of the present study suggest that so 
far, low BMD is less likely to be regarded as one of the major 
risk factors for coronary artery disease, inspite of the numer-
ous experimental results suggesting an association between 
low BMD and vascular calcification. But the results in patients 
with MetS, might call attention to low BMD as a marker for 
CAC. However considering MetS with regards to coronary 
atherosclerosis; a low-grade inflammatory process with vis-
ceral obesity is strongly associated with coronary atheroscle-
rosis.
16)17) In this study, there was a significant correlation be-
tween CAC and MetS. This result is consistent with the result 
from the previous study which demonstrated the relationship 
Table 4. Independent predictors of coronary artery calcification in the 
total patients using a forward multiple logistic regression analysis
OR 95% CI p
Model including T-score 
  of L-spine
Age 1.148 1.111 to 1.1870 <0.001
Male 7.188 3.790 to 13.631 <0.001
Metabolic syndrome 2.850 1.642 to 4.9480 <0.001
Model including T-score 
  of femur
Age 1.148 1.111 to 1.1870 <0.001
Male 7.188 3.790 to 13.631 <0.001
Metabolic syndrome 2.850 1.642 to 4.9480 <0.001
Model including L-spine 
  and femur
Age 1.148 1.111 to 1.1870 <0.001
Male 7.188 3.790 to 13.631 <0.001
Metabolic syndrome 2.850 1.642 to 4.9480 <0.001
OR: odds ratio,  CI: confidence interval, L-spine: lumbar spine
Table 5. Independent predictors of coronary artery calcification in 
patients without metabolic syndrome using a forward multiple lo-
gistic regression analysis
OR 95% CI p
Model including T-score 
  of L-spine
Age 01.141 1.089 to 1.1950 <0.001
Male 10.101 4.165 to 24.496 <0.001
Diabetes mellitus 07.822 1.451 to 42.174 0.017
Hypertension 04.779 2.036 to 11.219 <0.001
Model including T-score 
  of femur
Age 01.141 1.089 to 1.1950 <0.001
Male 10.101 4.165 to 24.496 <0.001
Diabetes mellitus 07.822 1.451 to 42.174 0.017
Hypertension 04.779 2.036 to 11.219 <0.001
Model including L-spine 
  and femur
Age 01.141 1.089 to 1.1950 <0.001
Male 10.101 4.165 to 24.496 <0.001
Diabetes mellitus 07.822 1.451 to 42.174 0.017
Hypertension 04.779 2.036 to 11.219 <0.001
OR: odds ratio,  CI: confidence interval, L-spine: lumbar spine
Table 6. Independent predictors of coronary artery calcification in pa-
tients with metabolic syndrome using a forward multiple logistic re-
gression analysis
OR 95% CI p
Model including T-score 
  of L-spine
Age 1.139 1.080 to 1.2010 <0.001
Male 3.762 1.339 to 10.569 0.012
T-score of L-spine 0.740 0.550 to 0.9960 0.047
Model including T-score 
  of femur
Age 1.137 1.078 to 1.1990 <0.001
Male 3.800 1.354 to 10.663 0.011
T-score of femur 0.670 0.453 to 0.9920 0.045
Model including T-score 
  of L-spine and femur
Age 1.139 1.080 to 1.2010 <0.001
Male 3.762 1.339 to 10.569 0.012
T-score of L-spine 0.740 0.550 to 0.9960 0.047
OR: odds ratio,  CI: confidence interval, L-spine: lumbar spineHyung Tak Lee, et al.   81
between CAC and Mets.
18-20) It has also been shown that insu-
lin resistance and atherosclerosis share a common inflamma-
tory mechanism.
6)
Specifically in this study, an independent relationship was 
found between CAC and BMD, only in patients with MetS. 
Chronic low-grade inflammatory processes or mediators are 
also known to be involved in the mechanism by which low 
BMD contributes in the pathogenesis of atherosclerosis. IL-6 
and oxidized LDL are reported to be involved in vascular cal-
cification by osteogenic de-differentiation of vascular smooth 
muscle cells.
21) Potentially, low BMD could provide a milieu fa-
voring vascular calcification through impaired phosphorous 
and calcium metabolism. Theoretically, there may be three 
possible explanations for interpreting this finding. Firstly, 
both the inflammatory process and impaired calcium/phos-
phorous metabolism are essential for CAC. This is less likely 
because MetS alone is independently associated with CAC. 
Secondly, even with an impaired calcium/phosphorus metab-
olism, MetS plays a permissive role in the pathogenesis of CAC. 
Thirdly, there might be a synergistic interaction between MetS 
and BMD. Since there was no synergistic interaction between 
BMD and MetS in this study, we can speculate that impaired 
calcium/phosphorous metabolism aggravates the pathogen-
esis of CAC only with accompanying MetS, associated with 
the chronic low-grade inflammation, whereas impaired calci-
um/phosphorous metabolism alone does not trigger the pa-
thogenesis of CAC.
However, there are some limitations to our study. The major 
limitation is the possibility of a type II error due to the small sam-
ple size. Also because of the cross-sectional design of this study, 
we cannot conclude whether low BMD is pathogenetically 
linked to coronary calcification or it just represents one of the 
markers for subclinical coronary atherosclerosis in patients 
with MetS. Secondly in this study, the criteria of waist circum-
ference was not used. Although use of ATP III criteria to de-
fine MetS in Korean populations
11) is not appropriate, since 
we have used  measures of BMI instead of waist circumference 
there is a possibility that we may have misclassified some sub-
jects who would have been classified differently based on meas-
ures of waist circumference. Thirdly, since data on menopause 
was not available, we could not include menopause status as 
a variable in the multiple logistic regression analysis models. 
Some reports have shown that estrogen deficiency could pos-
sibly affect both vascular calcification and osteoporosis in wo-
men.
22) Due to the possibility that the confounding factor was 
not fully adjusted, these findings cannot be applied to peri-
menopausal women. Fourthly, serum inflammatory marker 
such as hs-CRP, known to trigger the pathogenesis of CAC, was 
not available in this study. Hence , we could not demonstrate 
the direct relationship of vascular inflammation and CAC.
In conclusion, BMD is an independent determinant of CAC 
in patients with MetS. This finding suggests that it may there-
fore be meaningful to check for the presence of MetS, when 
evaluating patients with low BMD for the risk of developing 
coronary artery disease. 
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